NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing special-purpose nanomaterials for antiviral therapy, reported fiscal year 2026 results on Tuesday, highlighting regulatory and clinical progress for its broad-spectrum antiviral candidate NV-387. The company received regulatory approval in the Democratic Republic of Congo (DRC) for Phase II trials evaluating NV-387 Oral Gummies for the treatment of Mpox and Ebola, with both trials beginning enrollment at the end of September 2026. This milestone positions NanoViricides to test a single drug against multiple high-consequence viral pathogens, a strategy that could streamline outbreak response and reduce reliance on virus-specific treatments.
The DRC approval is significant because Mpox and Ebola are endemic in parts of Africa and have the potential to spread globally. Successful Phase II trials could pave the way for NV-387 to become a first-line defense against these diseases, especially in resource-limited settings where oral gummies are easier to administer than injectables. The trials will assess safety and efficacy, and positive results could attract further funding and partnerships.
In addition to the DRC trials, NanoViricides received U.S. Food and Drug Administration Orphan Drug Designation and Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles. These designations provide incentives such as tax credits, user fee waivers, and potential market exclusivity, which are crucial for a small biotech advancing a drug with broad-spectrum potential. Measles, though vaccine-preventable, still causes outbreaks worldwide, and a targeted antiviral could complement vaccination efforts, particularly for immunocompromised individuals.
Financially, NanoViricides reported approximately $2.79 million in cash and cash equivalents as of June 30, compared with approximately $1.67 million a year earlier. The company raised approximately $9.01 million through registered direct and at-the-market equity offerings during fiscal 2026, and subsequently raised approximately $3.8 million in July. It said it is pursuing additional funding through grants and contracts, partnerships, debt or equity financing. This improved cash position supports the ongoing Phase II trials and regulatory activities.
NanoViricides’ lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and measles. The company’s novel nanoviricide class of drug candidates is based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles.
The broader implications of NanoViricides’ progress extend beyond individual diseases. If NV-387 proves effective against multiple viruses, it could validate the nanoviricide platform as a versatile antiviral approach, potentially reducing the time and cost of developing treatments for emerging viral threats. This is particularly important as the world faces increasing frequency of outbreaks due to climate change, urbanization, and global travel.
Investors and industry observers can find more information about NanoViricides in the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/s000r. For those tracking the company’s progress, the latest updates are also shared through MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. For more information about MissionIR, visit www.MissionIR.com.
